An inflammatory cytokine signature predicts COVID-19 severity and survival
2020 · Nature Medicine · 2,683 citations
https://doi.org/10.1038/s41591-020-1051-9
D
Deepu Madduri
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
162
Papers
12.3K
Citations
35
h-index
71
i10-index
Deepu Madduri is an academic researcher from Johnson & Johnson (United States). The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Protein Degradation and Inhibitors. The author has an h-index of 35, co-authored 138 publications.
ORCID: 0000-0002-7305-9690Papers by this author
worksIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
2021 · New England Journal of Medicine · 2,258 citations
https://doi.org/10.1056/nejmoa2024850
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019 · New England Journal of Medicine · 1,675 citations
https://doi.org/10.1056/nejmoa1817226
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
2021 · The Lancet · 1,543 citations
https://doi.org/10.1016/s0140-6736(21)00933-8
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
2020 · Journal of Hematology & Oncology · 141 citations
https://doi.org/10.1186/s13045-020-00934-x
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
2023 · Journal of Clinical Oncology · 107 citations
https://doi.org/10.1200/jco.2023.41.16_suppl.8009
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat